Jilin Province Huinan Changlong Bio-pharmacy Co Ltd
HKEX:8049
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd
Cost of Revenue
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
J
|
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd
HKEX:8049
|
Cost of Revenue
-¥144.2m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-3%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Cost of Revenue
-¥1.5B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Cost of Revenue
-¥4.7B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-12%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Cost of Revenue
-¥29.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Cost of Revenue
-¥12.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-16%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Cost of Revenue
-¥259.1m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd
Glance View
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. engages in the manufacture and distribution of Chinese medicines and pharmaceutical products. The company is headquartered in Tonghua, Jilin. The company went IPO on 2001-05-24. Its products are mainly sold under the brand names of Changlong and Qing Tong. Its primary products include tablets, capsules, bulk drug, membrane, pills, bulk drug, powder for injection, lyophilized powder for injection, small volume parenteral solutions, sterile bulk drug and solution. The firm is also engaged in the trading of biochemical medicine through its subsidiaries. Its principal subsidiaries include Jilin Province Huinan Changlong Pharmacy Trading Company Limited and Jilin Province Medicinal Plants Trading Company Limited.
See Also
What is Jilin Province Huinan Changlong Bio-pharmacy Co Ltd's Cost of Revenue?
Cost of Revenue
-144.2m
CNY
Based on the financial report for Dec 31, 2025, Jilin Province Huinan Changlong Bio-pharmacy Co Ltd's Cost of Revenue amounts to -144.2m CNY.
What is Jilin Province Huinan Changlong Bio-pharmacy Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-3%
Over the last year, the Cost of Revenue growth was 26%. The average annual Cost of Revenue growth rates for Jilin Province Huinan Changlong Bio-pharmacy Co Ltd have been 9% over the past three years , -10% over the past five years , and -3% over the past ten years .
